Journal of the National Comprehensive Cancer Network: JNCCN 09/2009; 7(8):838-81. · 4.24 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: High epidermal growth factor receptor (EGFR) expression in the primary tumor predicts poor survival in colorectal cancer. However, EGFR expression may be discordant in primary tumor versus nodal or distant metastasis. We evaluated prognostic values of high EGFR expression in nodal metastasis versus primary tumor tissue.
Tissue microarrays from 94 surgically resected colorectal primary tumors were analyzed for EGFR expression using immunohistochemistry along with 49 paired positive metastatic nodes and 19 distant metastases. Proportional odds regression and log-rank tests described the association of tumor stage and survival with EGFR, dichotomized to low expression (0, 1) versus high expression (2, 3).
High EGFR expression rates in the primary tumor, metastatic lymph node and distant metastases were 18%, 24%, and 21%, respectively. The concordance rate was 71% for stage III/IV patients. High EGFR expression in primary tumor was associated with higher tumor stage (odds ratio 4.3, P = 0.005) and thus predicted poor survival (P = 0.046). High EGFR expression in the primary tumor was not associated with survival in patients with stage III or IV disease, whereas high EGFR expression in metastatic lymph nodes was associated with relatively poor survival (P = 0.005), for both stage III (P = 0.002) and stage IV patients (P = 0.014). Concordant high EGFR expression in primary tumor and lymph nodes conferred added risk of death (P = 0.003), conversely, concordant EGFR-negative primary tumor and lymph node was protective (P = 0.097).
EGFR expression may be discordant among primary, nodes, and metastases in colorectal cancer. High EGFR expressions in metastatic lymph nodes seem to be more accurate in predicting survival than in primary or metastatic tissues.
American journal of clinical oncology 06/2009; 32(3):245-52. DOI:10.1097/COC.0b013e3181891326 · 2.61 Impact Factor
Journal of the National Comprehensive Cancer Network: JNCCN 11/2007; 5(9):884-925. · 4.24 Impact Factor
Journal of the National Comprehensive Cancer Network: JNCCN 11/2007; 5(9):940-81. · 4.24 Impact Factor
Journal of the National Comprehensive Cancer Network: JNCCN 08/2005; 3(4):468-91. · 4.24 Impact Factor